Clinical utility of RNA sequencing to resolve unusual GNE myopathy with a novel promoter deletion

20Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Introduction: UDP N-acetylglucosamine2-epimerase/N-acetylmannosamine-kinase (GNE) gene mutations can cause mostly autosomal-recessive myopathy with juvenile-onset known as hereditary inclusion-body myopathy (HIBM). Methods: We describe a family of a patient showing an unusual HIBM with both vacuolar myopathy and myositis without quadriceps-sparing, hindering diagnosis. We show how genetic testing with functional assays, clinical transcriptome sequencing (RNA-seq) in particular, helped facilitate both the diagnosis and a better understanding of the genotype-phenotype relationship. Results: We identified a novel 7.08 kb pathogenic deletion upstream of GNE using array comparative genomic hybridization (aCGH) and a common Val727Met variant. Using RNA-seq, we found only monoallelic (Val727Met-allele) expression, leading to ~50% GNE reduction in muscle. Importantly, α-dystroglycan is hypoglycosylated in the patient muscle, suggesting HIBM could be a “dystroglycanopathy.” Conclusions: Our study shows the importance of considering aCGH for GNE-myopathies, and the potential of RNA-seq for faster, definitive molecular diagnosis of unusual myopathies. Muscle Nerve, 2019.

Cite

CITATION STYLE

APA

Chakravorty, S., Berger, K., Arafat, D., Nallamilli, B. R. R., Subramanian, H. P., Joseph, S., … Hegde, M. (2019). Clinical utility of RNA sequencing to resolve unusual GNE myopathy with a novel promoter deletion. Muscle and Nerve, 60(1), 98–103. https://doi.org/10.1002/mus.26486

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free